CorMedix Inc. — Director's Dealing 2013

Aug 22, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CorMedix Inc. (CRMD)
CIK: 0001410098
Period of Report: 2013-08-20

Reporting Person: Lefkowitz Steven W (Director, Interim Chief Financial Office)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-08-22	Common Stock, $0.001 par value per share	A	5800	$0.95	Acquired	61072	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2013-08-20	Warrant (right to purchase Common Stock)	$3.4375	P	5000	Acquired	2015-03-24	Common Stock, $0.001 par value per share (5000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $0.001 per share	10000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.9	2023-03-20	Common Stock, $0.001 par value per share (120000)	120000	Direct
Stock Option (right to buy)	$0.68	2022-12-05	Common Stock, $0.001 par value per share (150000)	150000	Direct
Senior Convertible Note (convertible into Common Stock)	$0.35	2013-11-13	Common Stock, $0.001 par value per share (42857)	0	Direct
Warrant (right to purchase Comm Stock)	$0.4	2017-11-13	Common Stock, $0.001 par value per share (37500)	0	Direct
Senior Convertible Note (convertible into Common Stock)	$0.35	2013-09-20	Common Stock, $0.001 par value per share (100000)	0	Indirect
Warrant (right to purchase Common Stock)	$0.4	2017-09-20	Common Stock, $0.001 par value per share (87500)	0	Indirect
Stock Option (right to buy)	$0.29	2022-01-06	Common Stock, $0.001 par value per share (30000)	30000	Direct
Stock Option (right to buy)	$1.1	2021-08-11	Common Stock, $0.001 par value per share (30000)	30000	Direct
Warrant	$3.4375	2015-03-24	Common Stock, $0.001 par value per share (19536)	19536	Direct

Footnotes

F1: These options vest quarterly over two years beginning June 13, 2013.

F2: These options vest as follows: fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, if the CE Mark approval is obtained on or before June 30, 2013, and (b) fifty percent (50%) on December 31, 2013.

F3: The reporting person beneficially owns these securities through Wade Capital Corporation (an entity for which he has voting and investment control).

F4: The options vest in full on the first anniversary of the date of grant.

F5: The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.

F6: (Right to buy Common Stock, $0.001 par value per share)

F7: The warrants were issued as part of the Company's initial public offering in March 2010 and were exercisable beginning six months after the effective date of the Company's registration statement related thereto.

F8: This report does not reflect 20,000 shares underlying a warrant which warrant was incorrectly reported as being owned by the reporting person's wife in a Form 3 filed on August 15, 2011.